使用生物标志物识别急性肾损伤以助在感染患者中检测脓毒症
该研究为回顾性国际Sapphire研究,纳入入ICU时无AKI证据的成人,按入组时临床诊断分为脓毒症组(n=216)、感染无脓毒症组(n=120)和无感染组(n=387)。主要发现:3天内发生2-3期AKI者30天死亡率23%,无者为14%;该差异在感染无脓毒症组最大(34% vs 11%;OR 4.09;95%CI 1.53-11.12;P=0.005)。在感染无脓毒症组,尿TIMP-2×IGFBP7 cutoff 2.0 units阳性者14例(11.7%),其中10例(71.4%)发生2-3期AKI,阳性结果较肌酐或尿量显现AKI的中位提前19小时(IQR 0.8-34.0 hr)。结论提示该检测或有助于在临床标准显现AKI前近一天识别感染患者的AKI,从而辅助脓毒症检测。
要点
- 入ICU时无AKI的感染但未临床诊断脓毒症患者中,尿TIMP-2×IGFBP7≥2.0 units者14例(11.7%),其中10例(71.4%)后续发生2-3期AKI。
- 该阳性检测结果较血清肌酐或尿量显现AKI中位提前19小时(IQR 0.8-34.0 hr),提示可提前识别器官功能障碍。
- 感染无脓毒症组中,3天内发生2-3期AKI者30天死亡率34%,无者为11%(OR 4.09;95%CI 1.53-11.12;P=0.005)。
- 全部人群合并分析,3天内发生2-3期AKI者30天死亡率23%,无者为14%。
- 以cutoff 1.0预测任何分期AKI获得相似结果。
适用人群与场景
- 成人入住ICU且入组时无急性肾损伤证据者。
- 按入组时临床诊断分为脓毒症组(n=216)、感染无脓毒症组(n=120)和无感染组(n=387)。
- 场景为学术医疗中心ICU;原文未提及急诊或院前场景。
诊断标准与关键阈值
- 脓毒症临床诊断由临床判定,原文未列出具体诊断标准条目。
- AKI分期依据血清肌酐或尿量临床标准,原文未列出具体界值。
- 尿TIMP-2×IGFBP7 cutoff 2.0 units用于预测感染无脓毒症患者发生2-3期AKI(作为脓毒症定义性器官衰竭);cutoff 1.0用于预测任何分期AKI。
处置流程与药物剂量
- 原文未提及具体处置流程或药物剂量;结果为回顾性观察,未提供基于生物标志物的治疗干预方案。
红旗征与不能漏的情况
- 感染但入ICU时未达脓毒症临床诊断者,若尿TIMP-2×IGFBP7≥2.0 units提示即将发生2-3期AKI(中位提前19小时),需警惕器官功能障碍进展。
- 感染无脓毒症组中3天内发生2-3期AKI者30天死亡率34%(vs 11%;OR 4.09;95%CI 1.53-11.12;P=0.005),提示该类患者死亡风险高。
研究设计与关键结果
- 研究类型:回顾性、国际、Sapphire研究;单中心学术医疗中心;样本为入ICU时无AKI的成人,分为脓毒症组n=216、感染无脓毒症组n=120、无感染组n=387。
- 主要观察:30天死亡率按3天内是否发生2-3期AKI分层;全部人群合并,发生2-3期AKI者30天死亡率23%,无者为14%。
- 感染无脓毒症组差异最大:发生2-3期AKI者30天死亡率34% vs 11%(OR 4.09;95%CI 1.53-11.12;P=0.005)。
- 在感染无脓毒症组,尿TIMP-2×IGFBP7 cutoff 2.0 units阳性14例(11.7%),其中10例(71.4%)发生2-3期AKI;阳性较肌酐或尿量显现AKI中位提前19小时(IQR 0.8-34.0 hr)。
- cutoff 1.0用于任何分期AKI获得相似结果;原文未报告该cutoff的具体例数或效应量。
证据类型、等级与局限
- 证据类型:回顾性国际研究(Sapphire研究),非随机对照试验。
- 局限:回顾性设计;单中心学术医疗中心;样本量有限(感染无脓毒症组n=120,cutoff 2.0阳性仅14例);原文未提及盲法或前瞻性验证。
对床旁实践的改变
- 对入ICU时无AKI的感染患者,若临床尚未诊断脓毒症,可考虑检测尿TIMP-2×IGFBP7以提前识别即将发生的2-3期AKI(中位提前19小时),辅助脓毒症器官衰竭判定。
- 该检测阳性提示后续AKI及死亡风险增高(感染无脓毒症组2-3期AKI者30天死亡率34%),但原文未提供基于该标志物的治疗干预方案,不能据此改变治疗策略。
- 适用人群为入ICU时无AKI证据的成人感染患者;原文未纳入儿童、已有AKI者或非ICU场景,不能外推。
- cutoff 2.0 units用于预测2-3期AKI,cutoff 1.0用于任何分期AKI;二者均为研究中的操作特征分析,非前瞻性验证的决策阈值。
指南或共识出处
- 原文未提及具体指南或共识名称;来源为Crit Care Med发表的Sapphire研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Although early recognition of sepsis is vital to improving outcomes, the diagnosis may be missed or delayed in many patients. Acute kidney injury is one of the most common organ failures in patients with sepsis but may not be apparent on presentation. Novel biomarkers for acute kidney injury might improve organ failure recognition and facilitate earlier sepsis care.
DESIGN: Retrospective, international, Sapphire study.
SETTING: Academic Medical Center.
PATIENTS: Adults admitted to the ICU without evidence of acute kidney injury at time of enrollment.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We stratified patients enrolled in the Sapphire study into three groups-those with a clinical diagnosis of sepsis (n = 216), those with infection without sepsis (n = 120), and those without infection (n = 387) at enrollment. We then examined 30-day mortality stratified by acute kidney injury within each group. Finally, we determined the operating characteristics for kidney stress markers (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) for prediction of acute kidney injury as a sepsis-defining organ failure in patients with infection without a clinical diagnosis of sepsis at enrollment. Combining all groups, 30-day mortality was 23% for patients who developed stage 2-3 acute kidney injury within the first 3 days compared with 14% without stage 2-3 acute kidney injury. However, this difference was greatest in the infection without sepsis group (34% vs 11%; odds ratio, 4.09; 95% CI, 1.53-11.12; p = 0.005). Using a (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) cutoff of 2.0 units, 14 patients (11.7%), in the infection/no sepsis group, tested positive of which 10 (71.4%) developed stage 2-3 acute kidney injury. The positive test result occurred a median of 19 hours (interquartile range, 0.8-34.0 hr) before acute kidney injury manifested by serum creatinine or urine output. Similar results were obtained using a cutoff of 1.0 for any stage of acute kidney injury.
CONCLUSIONS: Use of the urinary (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) test could identify acute kidney injury in patients with infection, possibly helping to detect sepsis, nearly a day before acute kidney injury is apparent by clinical criteria.
参考来源
- Kellum JA, Artigas A, Gunnerson KJ, et al. Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With Infection. Crit Care Med. 2021. PMID: 33566467. doi:10.1097/CCM.0000000000004845
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。